Репродуктивная эндокринология (Apr 2017)

The new view on treatment of the infections of urogenital system of pregnant women with diabetes

  • Т. В. Авраменко,
  • А. В. Грибанов,
  • И. В. Кривущенко

DOI
https://doi.org/10.18370/2309-4117.2017.34.44-52
Journal volume & issue
no. 34
pp. 44 – 52

Abstract

Read online

The article discusses the application and effectiveness of drug Aflazin® manufactured by Valartin Pharma Ltd. as an antimicrobial therapy in pregnant women with diabetes mellitus in the II-III trimesters with uncomplicated urinary tract infection. In the course of the study, 91 women aged 18–40 years were examined. Patients were randomized into 2 groups: 45 women entered group I (main), and group II (comparisons) – 46 pregnant women. All women received basic antibiotic therapy used in the clinic for the treatment of chronic nonspecific urinary tract infections. Additionally, pregnant women from the comparison group received Aflazin® 1 capsule 2 times a day for 15 days. Characteristics of the clinical course of the disease in pregnant women of both groups were homogeneous. The main signs of uncomplicated urinary tract infection were frequent painful urination in small portions, pain in the lower abdomen and in the lumbar region, an increase in body temperature. In 80% of cases, when studying the bacterial culture of the urine of pregnant women, microorganisms were detected in various associations. After using the drug Aflazin®, changes in the immunological reactivity of the organism were revealed due to a decrease in the level of CD4+-helpers and an increase in the percentage of phagocytosis. There was a change in the microbial spectrum of the organism towards the disappearance of the pathological flora in the urine. In the course of the study, a positive dynamics of the subjective and objective state of the examined women was obtained, a good tolerability and safety of the drug was noted. Complex therapy, supplemented with Aflazin®, had a significant positive effect on the overall condition of pregnant women. Efficacy of treatment as sufficient or high was noted in 45 (97.8%) cases from 46 in the comparison group and in 20 (44.4%) cases from 45 in the main group. The results obtained make it possible to recommend Aflazin® for the complex treatment of nonspecific urinary tract infections in women with diabetes mellitus in the II and III trimesters of pregnancy.

Keywords